文摘
在这项研究中,哮喘患者的认知变化的疾病在临床哮喘与观察到的变化有关措施,以识别的阈值变化的临床哮喘措施完全超越了病人。这项研究包括281名哮喘病人,年龄在18 - 63岁,一项随机、安慰剂对照的临床试验的白三烯拮抗剂。改变有关:1)哮喘症状评分;2)吸入beta-agonist使用;3)在一秒用力呼气量(FEV1);和4)最大呼气流量(PEF)全球问题,查询整体改变开始研究以来,哮喘药物。额外的分析研究小组报告的差异最小的改善治疗(积极治疗与安慰剂),性别和年龄组。为每个病人平均最小可感知的改善措施是:1)-0.31分的症状评分,范围0 - 6;2)-0.81泡芙x天吸入beta-agonist用(1);3)0.23 L FEV1; and 4) 18.79 L x min(-1) for PEF. In general placebo-treated patients and older patients, who reported minimal improvement, experienced less mean improvement from baseline than active-treated patients and younger patients, who reported minimal improvement. Determining the minimal patient perceivable improvement value for a measure may be helpful to interpret changes. However, interpretation should be carried out cautiously when reporting a single value as a clinically important change.